Search

Displaying results 8801 - 8810 of 10000 in total
  1. Drug

    SB 11285

    go.drugbank.com/drugs/DB17511
    Investigational

    SB 11285 is a second-generation Stimulator of Interferon Genes (STING) agonist.

  2. Drug

    Ligufalimab

    go.drugbank.com/drugs/DB17542
    Investigational

    Ligufalimab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47. … It is under investigation in clinical trial NCT04900350 (A Trial of AK117 (Anti-cd47) in Patients With Myelodysplastic Syndrome).

  3. Drug

    FT-1101

    go.drugbank.com/drugs/DB17553
    Investigational

    FT-1101 is a novel Bromodomain and Extra-Terminal motif (BET) inhibitor. … [A257301] FT-1101 is under investigation in clinical trial NCT02543879 (Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies).

  4. Drug

    FF-10501-01

    go.drugbank.com/drugs/DB17554
    Investigational

    FF-10501-01 is a novel, selective inosine monophosphate dehydrogenase (IMPDH) inhibitor with anticancer activity. … [A257306] FF-10501-01 is under investigation in clinical trial NCT03486353 (A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome).

  5. Drug

    Nisevokitug

    go.drugbank.com/drugs/DB17561
    Investigational

    Nisevokitug is a monoclonal antibody targeted against transforming growth factor beta (TGFβ) under investigation in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety

  6. Drug

    Ad-CEA vaccine

    go.drugbank.com/drugs/DB17581
    Investigational

    Ad-CEA vaccine is a cancer immunotherapy composed of carcinoembryonic antigen (CEA).

  7. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs).

  8. Drug

    Hemoximer

    go.drugbank.com/drugs/DB17600
    Investigational

    Hemoximer is a modified version of hemoglobin that undergoes pyridoxylation, for the purpose of lowering the oxygen affinity, and coupling with polyoxyethylene (POE), to increase its molecular weight.

  9. Drug

    CY-1503

    go.drugbank.com/drugs/DB17605
    Investigational

    CY-1503 is a pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-Dglucopyranosyl unit, and one alpha-L-fucopyranosyl

  10. Drug

    CDX-1135

    go.drugbank.com/drugs/DB17607
    Investigational

    CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed by Avant Immunotherapeutics (now Celldex).